MA45684A - Protéine d'apport du cerveau - Google Patents
Protéine d'apport du cerveauInfo
- Publication number
- MA45684A MA45684A MA045684A MA45684A MA45684A MA 45684 A MA45684 A MA 45684A MA 045684 A MA045684 A MA 045684A MA 45684 A MA45684 A MA 45684A MA 45684 A MA45684 A MA 45684A
- Authority
- MA
- Morocco
- Prior art keywords
- supply protein
- brain supply
- brain
- protein
- supply
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651065 | 2016-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45684A true MA45684A (fr) | 2019-05-22 |
Family
ID=59593007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045684A MA45684A (fr) | 2016-07-14 | 2017-07-13 | Protéine d'apport du cerveau |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11498974B2 (fr) |
| EP (1) | EP3484918A1 (fr) |
| JP (2) | JP2019529345A (fr) |
| KR (1) | KR20190039696A (fr) |
| CN (1) | CN109476728A (fr) |
| AU (1) | AU2017297804A1 (fr) |
| BR (1) | BR112019000098A2 (fr) |
| CA (1) | CA3028035A1 (fr) |
| IL (1) | IL263773A (fr) |
| MA (1) | MA45684A (fr) |
| MX (1) | MX2019000529A (fr) |
| PH (1) | PH12018502451A1 (fr) |
| RU (1) | RU2019102746A (fr) |
| SG (2) | SG10201912842VA (fr) |
| WO (1) | WO2018011353A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016989A2 (pt) | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| CA3118692A1 (fr) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Therapie genique de maladies neurodegeneratives a base de cellules |
| KR20220164773A (ko) * | 2020-04-08 | 2022-12-13 | 앨리어다 테라퓨틱스, 인코포레이티드 | 혈액-뇌 장벽 전달용 조성물 및 방법 |
| WO2022258841A1 (fr) | 2021-06-11 | 2022-12-15 | Bioarctic Ab | Molécule de liaison bispécifique |
| AU2022428997A1 (en) * | 2021-12-31 | 2024-08-15 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| EP4519317A1 (fr) * | 2022-05-05 | 2025-03-12 | Eli Lilly and Company | Molécules de liaison multispécifiques et leurs méthodes d'utilisation |
| WO2024080843A1 (fr) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et son utilisation |
| WO2024123052A1 (fr) * | 2022-12-08 | 2024-06-13 | 주식회사 아델 | Protéine de fusion comprenant un anticorps anti-tau et un peptide et utilisation associée |
| EP4688846A1 (fr) | 2023-03-24 | 2026-02-11 | BioArctic AB | Anticorps se liant au domaine de type protéase du récepteur de transferrine humaine htfr1 |
| WO2024263567A2 (fr) * | 2023-06-21 | 2024-12-26 | Eli Lilly And Company | Composés pour l'administration de granuline à travers la barrière hémato-encéphalique |
| WO2025007703A1 (fr) * | 2023-07-04 | 2025-01-09 | Beijing Neox Biotech Limited | Anticorps anti-tfr1 et leurs utilisations |
| WO2025262228A1 (fr) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Molécule de liaison bispécifique |
| US20260035475A1 (en) | 2024-06-20 | 2026-02-05 | Bioarctic Ab | Stabilized binding molecule |
| WO2026068519A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison sensible au ph |
| WO2026068532A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison bispécifique |
| WO2026068513A1 (fr) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Molécule de liaison bispécifique |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309341A2 (fr) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention et traitement de la maladie d'alzheimer |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| WO2008022349A2 (fr) * | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents pour barrière hémato-encéphalique |
| CA2722371C (fr) | 2008-04-24 | 2016-06-21 | Bristol-Myers Squibb Company | Utilisation de l'epothilone d dans le traitement des maladies associees a la proteine tau, y compris la maladie d'alzheimer |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| MX2011000009A (es) | 2008-07-10 | 2011-08-15 | Esbatech Alcon Biomed Res Unit | Metodos y composiciones para la administracion mejorada de macromoleculas. |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| CA2789963C (fr) * | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Anticorps se liant aux protofibrilles et utilisation associee dans des methodes therapeutiques et diagnostiques pour la maladie de parkinson, la demence a corps de lewy et d'autres alpha-synucleinopathies |
| ES2687706T3 (es) * | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la gripe |
| AR084020A1 (es) | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
| RU2711552C2 (ru) | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| KR102313341B1 (ko) * | 2013-08-26 | 2021-10-18 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 시알릴-루이스 a에 대한 사람 항체 코드화 핵산 |
| JP6744856B2 (ja) * | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| EP3166970B1 (fr) | 2014-07-10 | 2021-03-10 | BioArctic AB | Anticorps se liant aux protofibrilles ass améliorés |
-
2017
- 2017-07-13 RU RU2019102746A patent/RU2019102746A/ru not_active Application Discontinuation
- 2017-07-13 JP JP2019501707A patent/JP2019529345A/ja active Pending
- 2017-07-13 AU AU2017297804A patent/AU2017297804A1/en not_active Abandoned
- 2017-07-13 WO PCT/EP2017/067727 patent/WO2018011353A1/fr not_active Ceased
- 2017-07-13 KR KR1020197002785A patent/KR20190039696A/ko not_active Ceased
- 2017-07-13 BR BR112019000098-4A patent/BR112019000098A2/pt not_active Application Discontinuation
- 2017-07-13 SG SG10201912842VA patent/SG10201912842VA/en unknown
- 2017-07-13 SG SG11201810801QA patent/SG11201810801QA/en unknown
- 2017-07-13 CA CA3028035A patent/CA3028035A1/fr not_active Abandoned
- 2017-07-13 EP EP17751619.2A patent/EP3484918A1/fr not_active Withdrawn
- 2017-07-13 CN CN201780042832.1A patent/CN109476728A/zh active Pending
- 2017-07-13 MX MX2019000529A patent/MX2019000529A/es unknown
- 2017-07-13 MA MA045684A patent/MA45684A/fr unknown
- 2017-07-13 US US16/317,156 patent/US11498974B2/en active Active
-
2018
- 2018-11-21 PH PH12018502451A patent/PH12018502451A1/en unknown
- 2018-12-17 IL IL263773A patent/IL263773A/en unknown
-
2022
- 2022-06-30 JP JP2022106495A patent/JP7589194B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3028035A1 (fr) | 2018-01-18 |
| MX2019000529A (es) | 2020-01-15 |
| US11498974B2 (en) | 2022-11-15 |
| IL263773A (en) | 2019-02-28 |
| JP2019529345A (ja) | 2019-10-17 |
| AU2017297804A1 (en) | 2019-01-24 |
| US20190225699A1 (en) | 2019-07-25 |
| RU2019102746A (ru) | 2020-08-14 |
| SG11201810801QA (en) | 2019-01-30 |
| BR112019000098A2 (pt) | 2019-04-09 |
| PH12018502451A1 (en) | 2019-09-30 |
| CN109476728A (zh) | 2019-03-15 |
| RU2019102746A3 (fr) | 2020-11-30 |
| SG10201912842VA (en) | 2020-02-27 |
| JP7589194B2 (ja) | 2024-11-25 |
| KR20190039696A (ko) | 2019-04-15 |
| EP3484918A1 (fr) | 2019-05-22 |
| WO2018011353A1 (fr) | 2018-01-18 |
| JP2022130646A (ja) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45684A (fr) | Protéine d'apport du cerveau | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| EP3463146A4 (fr) | Ensembles chirurgicaux robotiques | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| KR20180085041A (ko) | 칫솔 | |
| EP3547968A4 (fr) | Prothèse obtenu par génie tissulaire | |
| EP3518708A4 (fr) | Structure d'assise souple | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| EP3437540A4 (fr) | Support d'endoscope | |
| HRP20190412T1 (hr) | Konstrukti proteina uspa2 i njihova upotreba | |
| DK3145946T3 (da) | Bakteriebaseret proteintilførsel | |
| MA50174A (fr) | Formules de protéines de fusion vegfr-fc | |
| HUE064240T2 (hu) | Fehérjetisztítás | |
| EP3487471A4 (fr) | Tétine artificielle de protection contre les morsures | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| DK3737402T5 (da) | Modificeret protein | |
| MA43873A (fr) | Dspositif d'injection | |
| EP3525479A4 (fr) | Casque d'écoute | |
| EP3583844A4 (fr) | Système d'aquaculture | |
| EP3512771A4 (fr) | Siège d'aéronef | |
| EP3431808A4 (fr) | Butée d'arrêt | |
| EP3445974A4 (fr) | Réchauffeur d'air | |
| EP3444345A4 (fr) | Dérivé d'arnmicro-143 | |
| ZA201902689B (en) | Therapeutic protein | |
| EP3343013A4 (fr) | Collecteur d'admission |